Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Assets: 2019-2024

Historic Assets for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $669.3 million.

  • Nurix Therapeutics' Assets rose 1.73% to $522.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $522.5 million, marking a year-over-year increase of 1.73%. This contributed to the annual value of $669.3 million for FY2024, which is 88.23% up from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Assets is $669.3 million, which was up 88.23% from $355.6 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Assets peaked at $669.3 million during FY2024, and registered a low of $355.6 million during FY2023.
  • Its 3-year average for Assets is $480.6 million, with a median of $416.8 million in 2022.
  • In the last 5 years, Nurix Therapeutics' Assets spiked by 799.80% in 2020 and then decreased by 14.68% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Assets stood at $396.3 million in 2020, then grew by 20.29% to $476.8 million in 2021, then decreased by 12.59% to $416.8 million in 2022, then declined by 14.68% to $355.6 million in 2023, then skyrocketed by 88.23% to $669.3 million in 2024.